CXXI.F Stock Overview
C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
C21 Investments Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.30 |
52 Week High | CA$0.47 |
52 Week Low | CA$0.20 |
Beta | 2.47 |
1 Month Change | -18.62% |
3 Month Change | -13.45% |
1 Year Change | 12.24% |
3 Year Change | -71.62% |
5 Year Change | n/a |
Change since IPO | 19.20% |
Recent News & Updates
Recent updates
Shareholder Returns
CXXI.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -6.0% | -1.5% | -3.2% |
1Y | 12.2% | 9.7% | 19.3% |
Return vs Industry: CXXI.F exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: CXXI.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
CXXI.F volatility | |
---|---|
CXXI.F Average Weekly Movement | 17.7% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CXXI.F's share price has been volatile over the past 3 months.
Volatility Over Time: CXXI.F's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Sonny Newman | www.cxxi.ca |
C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. The company offers packaged and wholesale vaporizer pens, flowers, cured resin extracts, edibles, pre-rolls, tinctures, and topicals. It also provides payroll and benefits services.
C21 Investments Inc. Fundamentals Summary
CXXI.F fundamental statistics | |
---|---|
Market cap | US$39.06m |
Earnings (TTM) | -US$2.55m |
Revenue (TTM) | US$28.77m |
1.2x
P/S Ratio-14.0x
P/E RatioIs CXXI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CXXI.F income statement (TTM) | |
---|---|
Revenue | US$28.77m |
Cost of Revenue | US$20.47m |
Gross Profit | US$8.30m |
Other Expenses | US$10.85m |
Earnings | -US$2.55m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.021 |
Gross Margin | 28.86% |
Net Profit Margin | -8.85% |
Debt/Equity Ratio | 3.5% |
How did CXXI.F perform over the long term?
See historical performance and comparison